Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of HLX26 plus serplulimab and chemotherapy in previously untreated advanced non-small cell lung cancer
CTR20231775Phase 2Active
- Sponsor
- Henlius
- Start
- Aug 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of hlx26, serplulimab in non-small cell lung cancer (NSCLC), sponsored by Henlius. Started Aug 2023; status: active.
02
Drugs
hlx26serplulimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20231775.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231775.